Palvella Therapeutics, Inc. PVLA
Set alert
152.00 USD +5.67 +3.87%
As of Nov 3, 12:06 PM ET
142.89 Day range 153.23
71.55 52-week range 161.38
- YTD
- +45.22%
- 1 year
- +97.81%
- Open
- 147.14
- Prev close
- 146.33
- Mkt cap
- 2.19B
- Vol
- 100.15K
- Avg vol
- 216.63K
- EPS
- -4.85
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 142.89
- High
- 153.23
- Forward P/E
- -18.51
- Beta
- 0.00
- Short ratio
- 9.92
- Inst. own
- 105.05%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 141.47
- 200-d avg
- 126.93
- 1y target
- 228.40
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 228.40 +50.3% upside
Now 152.00
- Target (low)
- 205.00
- Target (mean)
- 228.40
- Target (high)
- 267.00
Ratings (0m) 16 16 buy · 0 hold · 0 sell
- Strong buy0
- Buy16
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 16
- 1 month ago 15
- 2 months ago 15
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.73 | -2.31 – -1.05 | -1.03 | -68.1% | 0 | 0.0% | 13 |
| Next quarter | -2.04 | -2.73 – -1.21 | -1.08 | -89.1% | 0 | 0.0% | 13 |
| Current year | -6.39 | -7.84 – -3.95 | -3.71 | -72.2% | 0 | 0.0% | 13 |
| Next year | -7.91 | -13.52 – -1.54 | -6.39 | -23.8% | 24.63M | 0.0% | 11 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Oct 16, 2026 | William Blair | Initiated | — | Outperform |
| Oct 12, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 21, 2026 | Chardan Capital | Maintained | Buy | Buy |
| May 21, 2026 | Stephens & Co. | Reiterated | Overweight | Overweight |
| May 21, 2026 | Chardan Capital | Maintained | Buy | Buy |
| May 12, 2026 | Stephens & Co. | Initiated | — | Overweight |
| Mar 31, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Mar 24, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 16, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Feb 25, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Feb 25, 2026 | BTIG | Maintained | Buy | Buy |
| Feb 24, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Feb 24, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 29, 2026 | BTIG | Reiterated | Buy | Buy |
| Jan 16, 2026 | BTIG | Reiterated | Buy | Buy |
| Jan 7, 2026 | Mizuho | Initiated | — | Outperform |
| Dec 16, 2025 | Truist Securities | Maintained | Buy | Buy |
| Dec 16, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Dec 16, 2025 | TD Cowen | Maintained | Buy | Buy |
| Dec 16, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Dec 15, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Dec 15, 2025 | BTIG | Maintained | Buy | Buy |
| Dec 5, 2025 | Clear Street | Initiated | — | Buy |
| Dec 5, 2025 | BTIG | Initiated | — | Buy |
| Dec 4, 2025 | Craig-Hallum | Initiated | — | Buy |
| Nov 24, 2025 | Stifel | Maintained | Buy | Buy |
| Nov 19, 2025 | Raymond James | Upgrade | Outperform | Strong Buy |
| Nov 13, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 13, 2025 | Chardan Capital | Maintained | Buy | Buy |